GENOMIC RESOURCES FOR THE ZEBRAFISH

NIH GUIDE, Volume 26, Number 39, December 5, 1997

RFA:  DK-98-006

P.T.

National Institute of Diabetes and Digestive and Kidney Diseases
National Institute of Child Health and Human Development
National Cancer Institute
National Eye Institute
National Heart, Lung, and Blood Institute
National Human Genome Research Institute
National Institute of Alcohol Abuse and Alcoholism
National Institute on Deafness and Other Communication Disorders
National Institute on Drug Abuse
National Institute of General Medical Sciences
National Institute of Mental Health
National Institute of Neurological Disorders and Stroke
National Center for Research Resources

Letter of Intent Receipt Date:  March 6, 1998
Application Receipt Date:  April 10, 1998

PURPOSE

The purpose of this Request for Applications (RFA) is to solicit applications as
part of an effort to create resources that will facilitate the mapping and
positional cloning of genes in the zebrafish.  The specific objectives to be
accomplished are:  (1) the generation of a genetic map with a resolution of 0.3
cM or better; (2) the development of Expressed Sequence Tags (ESTs) both from
existing libraries and also from new cDNA libraries from specific developmental
time points and tissues generated under this RFA; and (3) creation of a physical
(radiation hybrid) map of the zebrafish genome.

This RFA is intended to stimulate development of a critical tool for research on
zebrafish.  Additional future initiatives are anticipated as part of the
trans-NIH effort to encourage work using this model system, and will build on the
present RFA.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health promotion
and disease prevention objectives of "Healthy People 2000," a PHS-led national
activity for getting priority areas.  This RFA, Generation of Genomic Resources
for the Zebrafish, is related to many priority areas.  Potential applicants may
obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0
or Summary Report: Stock No. 017-001-00473-1) through the Superintendent of
Documents, Government Printing Office, Washington, DC 20402-9325 (telephone:
202-512-1800).

ELIGIBILITY REQUIREMENTS

Applications may be submitted by domestic and foreign for-profit and non-profit
organizations, public and private, such as universities, colleges, hospitals,
laboratories, units of State and local governments, and eligible agencies of the
Federal government.  Racial/ethnic minority individuals, women, and persons with
disabilities are encouraged to apply as Principal Investigators.

MECHANISM OF SUPPORT

This RFA will use the National Institutes of Health (NIH) individual project
grant (R01) mechanism. Applications that address any one or all of the objectives
listed above are encouraged.  Because the NIH wishes to retain maximum
flexibility in organizing the best possible overall program, it is possible that,
in the case of an application proposing to address more than one objective, only
one component would be funded.  Therefore, applicants who propose to address more
than one of the objectives should organize the application in individual
sections, each describing the approach proposed for a single objective;
individual budgets also should be proposed for each objective.  A summary budget
for the entire application should be included, and the cover page should state
the total funds requested (direct and total costs).  All investigators funded
under this initiative will be expected to work together cooperatively so that the
resources developed will be of maximum usefulness to the community.

The total project period for applications submitted in response to the present
RFA may not exceed three years.  The anticipated award date is September 30,
1998.

This RFA is the result of a trans-NIH initiative with participation of the
Institutes listed above, working though the Cross-NIH Zebrafish Coordinating
Committee, under the co-chairmanship of the National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK) and the National Institute of Child Health
and Human Development (NICHD).  The principal awards will be made through the
NIDDK and will be managed by the NIDDK together with the National Human Genome
Research Institute (NHGRI) and the other participating institutes through the
Cross-NIH Zebrafish Coordinating Committee.

This RFA is a one-time solicitation.  Future applications will compete with all
investigator-initiated applications and be reviewed according to the customary
peer review procedures.

FUNDS AVAILABLE

Approximately $4.0 million (including direct and indirect costs) will be
available for this initiative in Fiscal Year 1998 and for each of the two
subsequent years.  It is anticipated that three to six awards will be made. 
Proposed funding levels are subject to change due to budgetary, administrative
and/or scientific considerations, and are dependent upon the receipt of a
sufficient number of applications of high scientific merit.  Although this
program is provided for in the financial plans of the participating ICs, the
award of grants pursuant to this RFA also is contingent upon the availability of
funds for this purpose.

RESEARCH OBJECTIVES

Background

Mutational analysis of development has proven to be a powerful tool to determine
the events that result in patterning and morphogenesis of the embryo.  As
experimentation in Drosophila melanogaster and Caenorhabditis elegans has
established, mutational studies combined with genetic combinatorial analyses can
identify specific genes that dictate embryonic development and clarify the
pathways in which they function.  The work in simple invertebrate systems has
established that remarkable evolutionary conservation exists of the genetic
programs that determine embryo formation, including such early patterning events
as formation of the embryonic axes, but also including later events such as
development of eye, heart, and other organs.  While the invertebrate systems are
extremely powerful, many aspects of patterning and morphogenesis of the
vertebrate embryo cannot be studied in these systems.  The vertebrate embryo has
many features not present in other models, including the substantially different
organization and greater complexity of the nervous system and the fact that some
vertebrate organs have no clear cognates in the simpler invertebrates.  Thus,
understanding human development will require application of experimental
approaches to the formation of the vertebrate embryo.  Some assessment of
mutations that affect development has been possible in the mouse, but the mouse
embryo is inaccessible in utero throughout much of its development. 
Consequently, mutational studies in this species have been largely limited to
defects in post-natal maturation.  In addition, the relatively long generation
time and substantial costs of maintaining large mouse colonies has limited the
applicability of genetic approaches.

The zebrafish, Danio rerio, has a number of valuable features as a model organism
for study of vertebrate development.  The embryos are transparent and accessible
throughout development.  It is possible to generate haploid progeny, which are
viable for up to five days, and also homozygous diploid progeny that carry only
maternal (or paternal) genetic information.  Many features of zebrafish
development have been characterized, including early embryonic patterning, and
some aspects of cell fate and lineage determination. Because of their relatively
short reproductive cycle, the large number of progeny that can be produced, and
the relatively small space needed to maintain large numbers of offspring, the
zebrafish is an efficient vertebrate model system for genetic analysis. Two
large-scale screens have been performed to date and the transparent embryos
screened for defects in overall embryonic pattern, morphogenesis or organ
formation.  As reported in the December 1996 issue of Development, these screens
have identified a substantial number of mutations that affect the formation of
organ systems, including defects in the nervous system, skeletal muscle,
craniofacial development, the kidney and endocrine organs, the cardiovascular and
gastrointestinal systems, and the sensory cells of lateral line systems relevant
to auditory and vestibular function.  For most of these mutations, the gene
defect has not yet been identified.  It is likely that many of these mutations
affect genes relevant to human development and disease processes such as cancer
and neurodegenerative diseases.

Some genomic resources already exist to facilitate identification of the
molecular defects that underlie these mutations.  The zebrafish genome is
estimated to consist of approximately 1.7 X 103 Mb or about 2,500 cM. Preliminary
analysis suggests large blocks of synteny between the zebrafish and human
genomes.  Currently, three genetic maps exist, consisting of approximately 500
microsatellite markers, 600 Random Amplified Polymorphic DNA markers (RAPDs), and
more than 125 mapped genes.  Several radiation hybrid (RH) panels have been
constructed, and their utility for large-scale physical mapping is currently
being evaluated.  It is anticipated that an RH panel of reasonable quality will
be available to the research community.  Large insert (BAC, PAC and YAC) genomic
libraries also exist and are publicly available. The utility of these resources
is limited, however, and the mapping infrastructure is insufficiently developed
to fully exploit the power of the genetics of this organism.

Objectives and Scope

The principle objective of this RFA is to solicit applications for research
projects that will use state-of-the-art methods, and that will develop any
necessary new technologies, to generate genetic and physical maps of the
zebrafish genome and to do so rapidly, efficiently, and at low cost.  These
objectives are set with a view towards providing genomic tools that will be used
by the community for the molecular identification of the genes responsible for
the existing mutant phenotypes.  Beyond this immediate utility, these resources
and tools ultimately can be applied to the comprehensive analysis of the complete
zebrafish genome.  Emphasis will be placed on the implementation of mechanisms
to ensure accessibility and ease of use of zebrafish genomic information.

1) Generation of an Improved Resolution Genetic Map

A high-resolution meiotic map would be invaluable for positional cloning of genes
revealed to be of interest by mutational screening.  This RFA seeks to place up
to 10,000 polymorphic markers on the zebrafish map.  The long-term objective is
to achieve a genetic map with the resolution of 0.1 cM; while the applicant need
not propose making a map of this resolution, it should be clear that continued
effort could produce such a map. The specific types of markers are not
stipulated, but could include RAPD's, CA repeats, single nucleotide polymorphisms
or other polymorphic markers.  Generation and mapping of polymorphisms associated
with cloned genes (including those identified by ESTs generated elsewhere under
this RFA) should be included in the proposal, as well as generation and mapping
of anonymous markers. The markers should be generated through the best available
procedures.  Applicants need to address the efficiency, throughput, robustness
and cost of the types of marker proposed, in addition to their scientific value.

Markers should be placed on meiotic panels derived from the progeny of a cross
between two strains.  The application may propose to map markers on existing
panels, or may propose creating new panels with enhanced polymorphism.  Choice
of strains should be justified.

Attention must be given in the application to the integration of any new map
information with existing maps, genetic and physical.  Provision must also be
made for distribution of mapping reagents to the community, and ensuring prompt
availability of map data to the community in coordination with informational
mechanisms implemented through this RFA (see Data and Resource Sharing below).

2) Generation of cDNA Resources and EST Sequencing

To provide additional markers for mapping, proposals are sought to generate and
sequence at least 100,000 Expressed Sequence Tags (ESTs) from multiple libraries. 
Besides their use in mapping, it is anticipated that these ESTs will provide a
generally useful resource for other areas of zebrafish research, including
functional analyses, candidate approaches to positional cloning, establishing
syntenic relationships between zebrafish and human, etc.  Initially this
sequencing should utilize currently available libraries, but to the extent that
new libraries are needed to optimize yield of new sequences, the production of
additional libraries should be undertaken, as described below.  Sequences should
be generated both from 5' ends of cDNAs, to clarify homologies with known genes,
and 3' ends, for the purposes of genetic mapping and SSCP analysis, with the
rationale for relative proportions of 5' and 3' sequence explained in the
application.  Applications should address how the strategy proposed will result
in maximizing the number of new gene sequences retrieved from a given library.

This RFA also seeks to supplement currently available cDNA libraries by the
generation of additional cDNA libraries from zebrafish at different stages of
development as well as from different tissues of the zebrafish.  These libraries,
in addition to their utility for generating ESTs, also will be useful reagents
for future functional studies outside the scope of this RFA.  Current technology
allows the production of representational libraries of partial genes or
production of more limited libraries of full-length clones, which are generally
enriched for shorter genes. In addition, technology exists to create normalized
(reduced redundancy) cDNA libraries; the application should justify the methods
proposed.  The specific mRNA source and method for cDNA library construction is
not stipulated.  The applicant should justify the type of libraries to be
constructed in terms of cost and general scientific utility.  Applicants must
also include provision to array and distribute the new cDNA libraries.

3) Generation of a Radiation Hybrid Map of the Zebrafish Genome

Applications are solicited for the placement of up to 5,000 markers (sequenced
genes, ESTs, etc.) on an available radiation hybrid panel. An RH map provides the
advantage that non-polymorphic markers can be readily mapped.  Applicants must
develop a cost-effective strategy for EST mapping and should justify the overall
allocation of resources to this component of the initiative.  Applicants must
make provision to integrate the RH map with existing genetic map information, to
distribute any mapping tools developed under this grant, and to disseminate
rapidly all mapping data in coordination with informational mechanisms
implemented through this RFA (see Data and Resource Sharing below).

A meiotic map of high resolution will be of primary utility in positional cloning
in the zebrafish, and it is anticipated that most resources available through
this RFA will be allocated to optimizing the genetic map. However, an integrated
RH map with a density of 5,000 markers will be a valuable adjunct to facilitate
positional candidate approaches to molecular cloning.

SPECIAL REQUIREMENTS

Data and Resource Sharing

The utility of genomic information to the community of investigators interested
in the zebrafish is heavily dependent upon the existence of mechanisms that
facilitate access to this information.  The sharing of materials and data in a
timely manner has been an essential element in the rapid progress made in
construction and use of the human and mouse genetic maps.  Public Health Service
policy requires that investigators make the results and accomplishments of funded
activities publicly available.  The advisors to the NIH and the DOE genome
programs have developed a set of "NIH-DOE Guidelines for Access to Mapping and
Sequencing Data and Material Resources" that address the special needs of genome
research.  These guidelines call for material and information from genome
research to be made available within six months of the time the data or materials
are generated.  More rapid sharing is encouraged and has become the norm in the
genome community.  Applications submitted in response to this RFA should include
detailed plans for sharing data and materials generated through the grant. 
Applicants particularly should propose information-handling mechanisms that
facilitate easy access to all known genetic and physical mapping data in an
integrated format.  Integration with the current bioinformatics zebrafish
database at the University of Oregon should be facilitated.

Since the ultimate use for these maps is to facilitate positional cloning,
provision should be made in the application for mechanisms to facilitate members
of the community in mapping genes.  This could include provision for distribution
of reagents created for meiotic mapping or acting as a service center to those
wishing to map genes.  Where appropriate, grantees may work with the private
sector in making unique resources available to the larger biomedical research
community at a reasonable cost.

The plans proposed for sharing and data release will be reviewed for adequacy by
NIH staff prior to award of the grant and the proposed sharing plan will be made
a condition of the award.  Investigators may request funds to defray the costs
of sharing materials or submitting data in their application.  Such requests must
be justified adequately.

Post-Award Management

During the course of the grant period, sequencing, mapping and other genomic
technologies will improve, and the rate of progress and focus of work supported
by projects may change.  It is expected that each Principal Investigator will
make any necessary adjustment in scientific direction to accommodate the changing
environment.  In order to ensure that the projects remain focused on appropriate
goals, maintain excellent coordination with the other projects funded under this
RFA, incorporate new technological advances and make sufficient progress,
scientific and programmatic visits to the grantees may be conducted by NIH staff. 
In addition, applications should include travel funds for the Principal
Investigators and the other key investigators on the grant to meet annually with
the Investigators on other projects funded through this RFA and with the
Cross-NIH Zebrafish Coordinating Committee in the Washington DC area.

LETTER OF INTENT

Prospective applicants are asked to submit, by March 6, 1998, a letter of intent
that includes a descriptive title of the proposed research; the name, address,
and telephone number of the Principal Investigator; the identities of other key
personnel and participating institutions; and the number and title of this RFA.

Although a letter of intent is not required, is not binding, and does not enter
into the review of a subsequent application, the information that it contains
allows NIH staff to estimate the potential review workload and avoid conflict of
interest in the review.

The letter of intent is to be sent to:

Chief, Office of Scientific Review
National Human Genome Research Institute
38 Library Drive, Room 609, MSC 6050
Bethesda, MD  20892-6050
Telephone:  (301) 402-0838
FAX:  (301) 408-2770

APPLICATION PROCEDURES

The research grant application form PHS 398 (rev. 5/95)
is to be used in applying for these grants.  Applications kits are available at
most institutional offices of sponsored research and may be obtained from the
Division of Extramural Outreach and Information Resources, National Institutes
of Health, 6701 Rockledge Drive, MSC 7910, Bethesda, MD 20892-7910, telephone
301/435-0714, email:  ASKNIH@od.nih.gov.

The RFA label available in the PHS 398 (rev. 5/95) application form must be
affixed to the bottom of the face page of the application.  Failure to use this
label could result in delayed processing of the application such that it may not
reach the review committee in time for review.  In addition, the RFA title and
number must be typed on line 2 of the face page of the application form and the
YES box must be marked.

Submit a signed, typewritten original of the application, including the
Checklist, plus three signed photocopies, in one package to:

CENTER FOR SCIENTIFIC REVIEW (formerly Division of Research Grants)
NATIONAL INSTITUTES OF HEALTH
6701 ROCKLEDGE DRIVE, ROOM 1040 - MSC 7710
BETHESDA, MD 20892-7710
BETHESDA, MD 20817 (for express/courier service)

At time of submission, two additional copies of the application must be sent to:

Chief, Office of Scientific Review
National Human Genome Research Institute
38 Library Drive, Room 609, MSC 6050
Bethesda, MD  20892-6050

Applications must be received by April 10, 1998.  If an application is received
after that date, it will be returned to the applicant without review.  The Center
for Scientific Review (CSR) will not accept any application in response to this
RFA that is essentially the same as one currently pending initial review, unless
the applicant withdraws the pending application.  The CSR will not accept any
application that is essentially the same as one already reviewed.  This does not
preclude the submission of substantial revisions of applications previously
reviewed, but such applications must include an introduction addressing the
previous critique.

REVIEW CONSIDERATIONS

Upon receipt, applications will be reviewed for completeness by CSR, and for
responsiveness by the participating ICs. Incomplete applications will be returned
to the applicant without further consideration.  If staff find that the
application is not responsive to the RFA, they will contact the applicant to
determine whether to return the application to the applicant or to submit it for
review in competition with unsolicited applications at the next review cycle.

Applications that are complete and responsive to the RFA will be evaluated for
scientific and technical merit by an appropriate peer review group convened by
NHGRI.  The review will evaluate applications in accordance with the criteria for
scientific/technical merit stated below.  As part of the initial merit review,
all applications will undergo a peer review streamlining process in which only
those applications deemed to have the highest scientific merit, generally the top
half of applications under review, will be discussed and assigned a priority
score.  Applications will receive a second level review by the National Advisory
Councils of the participating (ICs).  A written critique will be provided for all
applications, including those that are not discussed and not scored.  The NIH
will withdraw from further competition those applications that were unscored and
the applicant Principal Investigator and institutional official will be notified.

Staff will review the personnel category for appropriate staffing based on the
requested percent effort and any changes requested in future years.  The total
budget request will be reviewed for consistency with the proposed methods and
specific aims.  The duration of support will be reviewed to determine if it is
appropriate to ensure successful completion of the recommended scope of the
project.

Review Criteria

o  Significance: Does this study address the development of important genome
resources to the scientific community?  If the aims of the application are
achieved, how will it improve the physical or genetic map of the zebrafish?  What
will be the effect of these studies on the zebrafish resources?

o  Approach: Are the conceptual framework, design, methods, and analyses
appropriate and adequate to accomplish the aims of the project?  Does the
applicant acknowledge potential problem areas and consider alternative tactics?
Is the scientific and technical merit of the research proposed sufficient to
advance the objectives of the RFA?

o  Innovation: Does the project employ novel concepts, approaches or method? Are
the aims original and innovative?  Does the project challenge existing paradigms
or develop new methodologies or technologies?

o  Investigator: Are the Principal Investigator and staff appropriately trained
and well suited to carry out this work?  Is the work proposed appropriate to the
experience level of the principal investigator and other researchers (if any)?

o  Integration with other resources: Are the plans adequate to integrate the
resulting genome resources with those of other investigators and make them
available to the community in a timely manner?

o  Environment:  Does the scientific environment in which the work will be done
contribute to the probability of success?  Do the proposed experiments take
advantage of unique features of the scientific environment or employ useful
collaborative arrangements?  Is there evidence of institutional support?

o  Budget and duration: Are the proposed budget and duration appropriate in
relation to the proposed research?

Availability of special opportunities for furthering research programs through
the use of unusual talent resources, populations, or environmental conditions in
other countries which are not readily available in the United States or which
provide augmentation of existing U.S. resources will be considered in the review.

The initial review group also will examine the provisions for the protection of
human and animal subjects, and the safety of the research environment.

AWARD CRITERIA

The anticipated date of award is September 30, 1998.  Factors that will be used
to make award decisions are as follows:

o  Quality of the proposed project as determined by peer review;

o  Cost effectiveness of the proposed strategy;

o  Promise of the proposed program to accomplish the goals of this RFA and
address the needs of the participating ICs/Centers as regards their interest in
the zebrafish as a model organism;

o  Quality of the plans to cooperate and share data and resources with other
projects that may be funded under this RFA in a timely manner;

o  Availability of funds.

INQUIRIES

Written and telephone inquiries concerning this RFA are encouraged.  The
opportunity to clarify any issues or questions from potential applicants is
welcome.

Direct inquiries regarding programmatic issues to:

Dr. David G. Badman
Division of Kidney, Urologic and Hematologic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
45 Center Drive, Room 6AS-13C MSC 6600
Bethesda, MD  20892-6600
Telephone:  (301) 594-7717
FAX:  (301) 480-3510
Email:  David_Badman@nih.gov

Dr. Adam Felsenfeld
National Human Genome Research Institute
38 Library Drive, Room 614, MSC 6050
Bethesda, MD  20892-6050
Telephone:  (301) 496-7531
FAX:  (301) 480-2770
Email:  felsenfa@odder.nhgri.nih.gov

Programmatic contacts for the other participating ICs are:

Dr. Deborah Henken
Center for Research for Mothers and Children
National Institute for Child Health and Human Development
6100 Executive Boulevard, Room 4B01 MSC-7510
Bethesda, MD  20892-7510
Telephone:  (301) 496-5541
FAX:  (301) 402-4083
Email:  HenkenD@hd01.nichd.nih.gov

Dr. Grace L. Shen
Division of Cancer Biology
National Cancer Institute
6130 Executive Boulevard, Room 501
Rockville, MD  20892-7381
Telephone:  (301) 435-5226
FAX:  (301) 496-8656
Email:  gs35r@nih.gov

Dr. Judith H. Greenberg
Division of Genetics and Developmental Biology
National Institute of General Medical Sciences
45 Center Drive, MSC 6200
Bethesda, MD  20892-6200
Telephone: (301) 594-0943
FAX:  (301) 480-2228
Email:  greenbej@nigms.nih.gov

Dr. Carol H. Letendre
Division of Blood Diseases and Resources
National Heart, Lung, and Blood Institute
6701 Rockledge Drive, MSC 7950
Bethesda, MD  20892-7950
Telephone:  (301) 435-0080
FAX:  (301) 480-0867
Email:  letendrc@gwgate.nhlbi.nih.gov

Dr. Maria Y. Giovanni
Fundamental Retinal Processes
National Eye Institute
Executive Plaza South, Suite 350 - MSC 7164
Bethesda, MD  20892-7164
Telephone:  (301) 496-0484
FAX:  (301) 402-0528
Email:  myg@nei.nih.gov

Dr. Robert W. Karp
Division of Basic Research
National Institute on Alcohol Abuse and Alcoholism
6000 Executive Boulevard, Suite 402, MSC 7003
Bethesda, MD  20892-7003
Telephone:  (301) 443-4223
FAX:  (301) 594-0673
Email:  rkarp@willco.niaaa.nih.gov

Dr. Judy A. Small
Division of Fundamental Neurosciences and Developmental Disorders
National Institute of Neurological Disorders and Stroke
7550 Wisconsin Avenue, Room 8C04
Bethesda, MD  20892-9170
Telephone:  (301) 496-5821
FAX:  (301) 402-0887
Email:  js134h@nih.gov

Dr. Chyren Hunter
Division of Human Communication
National Institute on Deafness and Other Communication Disorders
6120 Executive Boulevard, Room 400-C, MSC-7180
Bethesda MD  20982-7180
Telephone:  (301) 402-3461
FAX:  (301) 402-6251
Email:  Chyren_Hunter@nih.gov

Dr. Theresa Lee
Division of Basic Research
National Institute on Drug Abuse
5600 Fishers Lane, Room 10A19
Rockville, MD  20857
Telephone:  (301) 443-6300
FAX:  (301) 594-6043
Email:  tl37h@nih.gov

Dr. Steven O. Moldin
Division of Basic and Clinical Neuroscience Research
National Institute of Mental Health
5600 Fishers Lane, Room 10C-26
Rockville, MD  20857
Telephone:  (301) 443-2037
FAX:  (301) 443-9890
Email:  smoldin@nih.gov

Dr. Elaine Young
Comparative Medicine
National Center for Research Resources
6705 Rockledge Drive, Room 6164 MSC 7965
Bethesda, MD  20892-7965
Telephone:  (301) 435-0776
FAX:  (301) 480-3659
Email:  elainey@ep.ncrr.nih.gov

Direct inquiries regarding fiscal and administrative matters to:

Aretina Perry-Jones
Division of Extramural Activities
National Institute of Diabetes and Digestive and Kidney Diseases
45 Center Drive, Room 6AN-38B, MSC 6600
Bethesda, MD  20892-6600
Telephone:  (301) 594-8862
FAX:  (301) 480-3504
Email:  PerryA@extra.niddk.nih.gov

Fiscal and administrative contacts for the other participating ICs are:

Mr. E. Douglas Shawver
Grants Management Branch
National Institute for Child Health and Human Development
6100 Executive Boulevard, Room 8A17, MSC-7510
Bethesda, MD  20892-7510
Telephone:  (301) 496-1303
FAX:  (301) 402-0915
Email:  Shawver@hd01.nichd.nih.gov

Mr. Bill Wells
Grants Administration Branch
National Cancer Institute
6120 Executive Boulevard, Room 243
Bethesda, MD  20892
Rockville, MD  20852 (express/courier service)
Telephone:  (301) 496-7800, ext. 250
FAX:  (301) 496-8601
Email:  WW14J@NIH.gov

Ms. Marcia Cohn
Grants Management Office
National Institute of General Medical Sciences
45 Center Drive, Room 2AN-44E, MSC 6200
Bethesda, MD  20892-6200
Telephone:  (301) 594-3918
FAX:  (301) 480-1969
Email:  cohnm@nigms.nih.gov

Ms. Jean Cahill
Grants Management Office
National Human Genome Research Institute
38 Library Drive, Room 613, MSC 6050
Bethesda, MD  20892-6050
Telephone:  (301) 402-0733
FAX:  (301) 402-1951
Email:  cahillj@odder.nhgri.nih.gov

Ms. Jane R. Davis
Division of Extramural Affairs
National Heart, Lung, and Blood Institute
6701 Rockledge Drive, MSC 7926
Bethesda, MD  20892-7926
Telephone:  (301) 435-0166
FAX:  (301) 480-3310
Email:  jane_davis@nih.gov

Ms. Carolyn E. Grimes
Grants Management Branch
National Eye Institute
Executive Plaza South, Suite 350, MSC 7164
Bethesda, MD  20892-7164
Telephone:  (301) 496-5884
FAX:  (301) 496-9997
Email:  cegrimes@nei.nih.gov

Ms. Linda Hilley
Office of Planning and Resource Management
National Institute on Alcohol Abuse and Alcoholism
6000 Executive Boulevard, Suite 504, MSC 7003
Bethesda, MD  20892-7003
Telephone:  (301) 443-4703
FAX:  (301) 443-3891
Email:  lhilley@willco.niaaa.nih.gov

Ms. Tina Carlisle
Grants Management Branch
National Institute of Neurological Disorders and Stroke
Federal Building, Room 1004
Bethesda, MD  20892-9190
Telephone:  (301) 496-9231
FAX:  (301) 402-0218
Email:  tc48k@nih.gov

Ms. Sharon Hunt
Grants Management Office
National Institute on Deafness and Other Communication Disorders
6120 Executive Boulevard, Room 400-B, MSC-7180
Bethesda, MD  20982-7180
Telephone:  (301) 402-0909
FAX:  (301) 402-1758
Email:  SH79F@nih.gov

Ms. Catherine Mills
Grants Management Branch
National Institute on Drug Abuse
5600 Fishers Lane,  Room  8A-54
Rockville, MD  20857
Telephone:  (301) 443-6710
FAX:  (301) 594-6847
Email:  cm108w@nih.gov

Ms. Diana S. Trunnell
Grants Management Branch
National Institute of Mental Health
5600 Fishers Lane, Room 7C-08
Rockville, MD  20857
Telephone:  (301) 443-2805
FAX:  (301) 443-6885
Email:  dt21a@nih.gov

Ms. Louise Amburgey
Office of Grants Management
National Center for Research Resources
6705 Rockledge Drive, Room 6086 MSC 7965
Bethesda, MD  20892-7965
Telephone:  (301) 435-0844
FAX:  (301) 480-3777
Email:  louisem@ep.ncrr.nih.gov

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic Assistance No.
93.849 (Kidney, Urologic and Hematologic Research).  Awards are made under
authorization of the Public Health Service Act, Title IV, Part A (Public Law
78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered
under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74. 
This program is not subject to the intergovernmental review requirements of
Executive Order 12372 or Health Systems Agency review.

The PHS strongly encourages all grant and contract recipients to provide a
smoke-free workplace and promote the non-use of all tobacco products.  In
addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in
certain facilities (or in some cases, any portion of a facility) in which regular
or routine education, library, day care, health care or early childhood
development services are provided to children.  This is consistent with the PHS
mission to protect and advance the physical and mental health of the American
people.


Return to Volume Index

Return to NIH Guide Main Index


Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy


Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.